INDIRECT COMPARISON OF PEMBROLIZUMAB TO VEMURAFENIB AND DABRAFENIB MONOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BRAF MUTATION POSITIVE IPILIMUMAB NAIVE PATIENTS

被引：1
|
作者：
Jansen, J. P. [1 ]
Stevinson, K. [2 ]
Wang, J. [3 ]
机构：
[1] Precis Hlth Econ, San Francisco, CA USA
[2] Merck & Co Inc, Lebanon, NJ USA
[3] Merck & Co Inc, North Wales, PA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1650
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN28
引用
收藏
页码：A138 / A138
页数：1
相关论文
共 50 条
  • [31] First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
    Vladimir M. Moiseyenko
    Fedor V. Moiseyenko
    Grigoriy A. Yanus
    Ekatherina Sh. Kuligina
    Anna P. Sokolenko
    Ilya V. Bizin
    Alexey A. Kudriavtsev
    Svetlana N. Aleksakhina
    Nikita M. Volkov
    Vyacheslav A. Chubenko
    Kseniya S. Kozyreva
    Mikhail M. Kramchaninov
    Alexandr S. Zhuravlev
    Kseniya V. Shelekhova
    Denis V. Pashkov
    Alexandr O. Ivantsov
    Aigul R. Venina
    Tatyana N. Sokolova
    Elena V. Preobrazhenskaya
    Natalia V. Mitiushkina
    Alexandr V. Togo
    Aglaya G. Iyevleva
    Evgeny N. Imyanitov
    Clinical Drug Investigation, 2018, 38 : 553 - 562
  • [32] First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
    Moiseyenko, Vladimir M.
    Moiseyenko, Fedor, V
    Yanus, Grigoriy A.
    Kuligina, Ekatherina Sh
    Sokolenko, Anna P.
    Bizin, Ilya, V
    Kudriavtsev, Alexey A.
    Aleksakhina, Svetlana N.
    Volkov, Nikita M.
    Chubenko, Vyacheslav A.
    Kozyreva, Kseniya S.
    Kramchaninov, Mikhail M.
    Zhuravlev, Alexandr S.
    Shelekhova, Kseniya, V
    Pashkov, Denis, V
    Ivantsov, Alexandr O.
    Venina, Aigul R.
    Sokolova, Tatyana N.
    Preobrazhenskaya, Elena, V
    Mitiushkina, Natalia, V
    Togo, Alexandr, V
    Iyevleva, Aglaya G.
    Imyanitov, Evgeny N.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (06) : 553 - 562
  • [33] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
  • [34] Real world treatment patterns of first-line combination therapies among patients with metastatic melanoma and BRAF mutation.
    Qiu, Ying
    Li, Zhiyi
    Tang, Jackson
    Atanasov, Pavel
    Mahmood, Syed
    Grzegorzewski, Kris
    Chen, Lei
    Chen, Joyce S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma
    Thompson, J. A.
    Berman, D.
    Siegal, J.
    Minor, D.
    Amin, A.
    Ron, I.
    Ridolfi, R.
    Assi, H.
    Hamid, O.
    Weber, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists
    Atkinson, Victoria
    Long, Georgina V.
    Menzies, Alexander M.
    McArthur, Grant
    Carlino, Matteo S.
    Millward, Michael
    Roberts-Thomson, Rachel
    Brady, Benjamin
    Kefford, Richard
    Haydon, Andrew
    Cebon, Jonathan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 5 - 12
  • [37] Continuous temozolomide (TMZ) monotherapy as first-line treatment in patients with metastatic melanoma (MM)
    del Pozo, N.
    Blasco, A.
    Camps, C.
    Caballero, C.
    Estevez Garcia, P.
    Jantus, E.
    Marin, S.
    Oliver, V.
    Berrocal, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
    Kozak, K.
    Teterycz, P.
    Galus, L.
    Mackiewicz, J.
    Brandys, P.
    Cybulska-Stopa, B.
    Kempa-Kaminska, N.
    Zietek, M.
    Zubrowska, J.
    Dziura, R.
    Sobczuk, P.
    Czarnecka, A. M.
    Rutkowski, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S666 - S666
  • [39] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
12345